Received Oct 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | JB4K2 | — |
Engerix-B pediatric dose administration to an adult; Engerix-B pediatric dose administration to an adult; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 45-year-old female patient who received HBV (Engerix B pediatric) (batch number JB4K2, expiry date 23-JAN-2027) for prophylaxis. On 11-SEP-2025, the patient received Engerix B pediatric. On 11-SEP-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Engerix-B pediatric dose administration to an adult) and underdose (Verbatim: Engerix-B pediatric dose administration to an adult). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-SEP-2025 A health care provider had wanted to know how to proceed after having administered a pediatric dose of Engerix-B to an adult.